What is congenital mesoblastic nephroma?
Congenital mesoblastic nephroma (CMN) is a rare kidney tumour of newborn babies and young infants. It is the most common kidney tumour in the first few months of life, and it is often found before birth on a pregnancy scan or in the first weeks after delivery.
CMN accounts for roughly 5% of all childhood kidney tumours (Vokuhl et al., 2018). It is considered a tumour of low malignant potential. In most babies, it does not spread, and removing the affected kidney cures it (Gooskens et al., 2017).
There are three types under the microscope: classic, cellular and mixed. The cellular type often carries a gene fusion called ETV6-NTRK3, the same change found in infantile fibrosarcoma, a soft tissue tumour of infants. This fusion can be targeted with modern drugs if the tumour comes back or cannot be removed.
Although the outlook is excellent, newborns are fragile, so the timing and type of treatment need careful planning by a specialist children’s cancer team.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Kidney tumour of infancy with low malignant potential |
| How common | About 5% of childhood kidney tumours |
| Typical age | Before birth to 3 months; most are diagnosed under 6 months |
| Sex | Slightly more common in boys |
| Subtypes | Classic, cellular and mixed |
| Key gene change | ETV6-NTRK3 fusion in many cellular tumours |
| Typical presentation | Abdominal lump, sometimes found on pregnancy scans |
| Main treatment | Surgical removal of the kidney (nephrectomy) |
| Outlook | Excellent; about 97% survival at 5 years |
2. The three subtypes
| Subtype | Share of cases | Appearance | Behaviour |
|---|---|---|---|
| Classic | About half | Bundles of bland spindle cells, like a fibrous scar | Very low risk of recurrence |
| Cellular | About a third | Densely packed cells with more cell division | Higher risk of recurrence, especially without the fusion |
| Mixed | The rest | Areas of both patterns | Intermediate |
Proportions come from a German and SIOP series of 111 children (Vokuhl et al., 2018).
3. Causes and risk factors
The cause of CMN is not known. It develops during pregnancy, while the baby’s kidney is still forming.
| Point | Details |
|---|---|
| Inheritance | Not inherited; parents did nothing to cause it |
| Gene fusion | ETV6-NTRK3 develops in the tumour cells of many cellular CMNs |
| Other gene changes | Some classic tumours carry changes in the EGFR gene |
| Link with infantile fibrosarcoma | The cellular type is thought to be the kidney counterpart of this tumour |
There is no known lifestyle, diet or environmental cause, and nothing can be done during pregnancy to prevent it.
4. How does it look
Before birth
| Feature | Description |
|---|---|
| Pregnancy scan | A solid mass in one of the baby’s kidneys |
| Polyhydramnios | Excess amniotic fluid around the baby is common |
| Early delivery | Premature birth occurs more often |
On scans after birth
| Feature | Description |
|---|---|
| Ultrasound | A solid kidney mass, sometimes with a ring of blood vessels around its edge |
| Size | Often large compared with the baby’s size |
| Cystic areas | More common in the cellular type |
| Spread | Usually none at diagnosis |
Under the microscope
| Feature | Classic | Cellular |
|---|---|---|
| Cells | Thin, bland spindle cells | Plump, crowded cells |
| Pattern | Interlacing bundles that extend into the kidney | Sheets with pushing borders |
| Mitoses | Few | Many |
| Fusion test | Negative | Positive in more than half |
5. Symptoms
Common signs in babies
- A firm lump in the tummy, often noticed by parents or at the newborn check
- A swollen abdomen
- High blood pressure, which may only be found on testing
- Blood in the urine (less common)
- Vomiting or poor feeding, when the tumour presses on the gut
Signs related to the tumour’s chemicals
| Problem | What it means |
|---|---|
| High calcium (hypercalcaemia) | May cause poor feeding, vomiting or constipation |
| High blood pressure | The tumour can release renin, a hormone that raises blood pressure |
| Increased urine output | Linked with high calcium or kidney effects |
During pregnancy
| Sign | Notes |
|---|---|
| Excess amniotic fluid | The mother’s tummy may grow faster than expected |
| Fetal distress or early labour | Occasionally |
When to seek medical advice
See a doctor if your baby has a lump or swelling in the tummy, blood in the nappy, repeated vomiting or poor feeding. Most tummy lumps in babies are caused by harmless conditions, but they always need a check.
Diagnosis before birth
When a kidney mass is seen on a pregnancy scan, the pregnancy is usually followed more closely in a fetal medicine unit. Doctors monitor the amount of amniotic fluid, the size of the mass and the baby’s wellbeing.
Parents meet the paediatric surgeons before delivery to plan care after birth. Most babies can be born vaginally, and delivery is planned at a hospital with neonatal intensive care and paediatric surgery on site.
6. Diagnosis
| Test | Purpose |
|---|---|
| Abdominal ultrasound | First scan; shows the solid kidney mass |
| MRI or CT | Shows the size, the blood vessels and the relationship to other organs |
| Chest imaging | Checks for rare lung spread |
| Blood tests | Kidney function, calcium, blood count |
| Blood pressure monitoring | Detects high blood pressure |
| Pathology after surgery | Confirms CMN and identifies the subtype |
| Molecular testing | Looks for the ETV6-NTRK3 fusion |
In most babies, the diagnosis is confirmed after the kidney is removed, rather than by needle biopsy. The main condition to tell apart is Wilms tumour, which is much more common in older infants and toddlers.
Kidney tumours in babies compared
| Tumour | Usual age | Typical treatment | Outlook |
|---|---|---|---|
| Congenital mesoblastic nephroma | Before birth to 6 months | Surgery alone in most cases | Excellent |
| Wilms tumour | Mostly 1-5 years; rare in newborns | Surgery and chemotherapy, sometimes radiotherapy | Very good |
| Rhabdoid tumour of the kidney | Usually under 2 years | Intensive multimodal treatment | Poor |
| Clear cell sarcoma of the kidney | Usually 1-4 years | Surgery, chemotherapy and radiotherapy | Good |
Staging
Childhood kidney tumours are usually staged after surgery:
| Stage | Description |
|---|---|
| Stage I | Tumour confined to the kidney and completely removed |
| Stage II | Tumour extends beyond the kidney but is completely removed |
| Stage III | Tumour left behind after surgery, tumour spill or lymph node involvement |
| Stage IV | Spread to distant organs (rare) |
7. Treatment
Treatment is carried out by a paediatric surgical and oncology team, often with neonatal intensive care specialists.
Surgery
| Aspect | Details |
|---|---|
| Operation | Removal of the affected kidney and tumour (radical nephrectomy) |
| Approach | Usually open surgery; keyhole surgery in selected cases |
| Goal | Complete removal without rupturing the tumour |
| Timing | Planned carefully in newborns, balancing tumour size with the baby’s stability |
Surgery alone cures most babies (Gooskens et al., 2017). A single-centre series of nine infants also concluded that surgery remains the mainstay, with chemotherapy and radiotherapy kept for tumours that cannot be removed or that come back (Pachl et al., 2020).
What to expect around surgery
| Stage | What happens |
|---|---|
| Before | Scans, blood tests and stabilisation of blood pressure and calcium |
| Anaesthetic | Given by a specialist paediatric anaesthetist |
| Operation | Usually takes a few hours |
| After | Care on a neonatal or paediatric intensive care unit or surgical ward |
| Feeding | Usually restarted within a few days |
| Going home | Often within a week or two, depending on the baby’s age and recovery |
| Results | The pathology report, including subtype and fusion status, follows within 1-2 weeks |
Treatment after surgery
| Situation | Usual approach |
|---|---|
| Classic or mixed CMN, completely removed | Follow-up only |
| Cellular CMN, completely removed | Usually follow-up only |
| Tumour left behind or ruptured | Close monitoring; chemotherapy may be considered |
| Recurrence or spread | Further surgery, chemotherapy, and sometimes radiotherapy |
Targeted treatment
For tumours with an NTRK fusion that cannot be removed or that recur, TRK inhibitors such as larotrectinib can shrink the tumour. These drugs are taken by mouth and are generally well tolerated. Kinase fusions in infantile tumours such as CMN are often sensitive to these targeted drugs (Davis et al., 2022).
Supportive care
| Problem | Management |
|---|---|
| High blood pressure | Medicines until the tumour is removed |
| High calcium | Fluids and medicines |
| Prematurity | Neonatal intensive care support |
| Feeding | Nutritional support before and after surgery |
8. Outlook (prognosis)
| Measure | Figure |
|---|---|
| 5-year overall survival | About 97% |
| 5-year relapse-free survival | About 93% |
| Classic type relapse-free survival | About 98% |
| Cellular type relapse-free survival | About 89% |
| Mixed type relapse-free survival | About 80% |
These figures come from 111 children treated in European studies (Vokuhl et al., 2018). All relapses in that series occurred in tumours without the ETV6-NTRK3 fusion. Among cellular tumours, those with the fusion did not relapse at all.
The main risks are recurrence within the first year, usually in cellular tumours, and complications of treatment in very young babies. The risk of treatment-related death is highest in the first weeks of life, which is why care in an experienced centre is important (Gooskens et al., 2017).
9. Follow-up
| Follow-up | Typical schedule |
|---|---|
| Abdominal ultrasound | Every few months in the first 1-2 years, when recurrences usually happen |
| Chest imaging | For higher-risk cases |
| Blood pressure and kidney function | Regularly, as the child grows with one kidney |
| Growth and development | Routine checks |
Long-term health
Most children treated for CMN grow up healthy. Because they have one kidney, doctors usually recommend lifelong attention to blood pressure, urine protein and kidney function. Children who needed chemotherapy or radiotherapy have additional long-term follow-up for late effects of those treatments.
10. Living with congenital mesoblastic nephroma
- One kidney is enough: children with a single healthy kidney usually grow and develop normally
- Check blood pressure at routine visits throughout childhood
- Tell other doctors that your child has one kidney
- Avoid unnecessary anti-inflammatory medicines unless advised by a doctor
- Encourage normal activity; discuss contact sports with your team when your child is older
- Keep vaccinations up to date unless your child’s team advises otherwise
- Keep copies of the surgery and pathology reports for future doctors
- Treat urine infections promptly, as they matter more when there is only one kidney
- Seek support from children’s cancer charities and family support services
Support for parents
| Need | Where to find help |
|---|---|
| Information | Your child’s specialist nurse and oncology team |
| Emotional support | Hospital psychologists, social workers and parent groups |
| Practical help | Charities offering travel, accommodation and financial advice |
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is CMN cancer? | It is a tumour with low malignant potential; most behave in a benign way after removal |
| Did something in pregnancy cause it? | No known cause in pregnancy has been identified |
| Will my next baby be affected? | It is not inherited, so the risk is not raised |
| Will my child need chemotherapy? | Usually not; it is kept for tumours that recur or cannot be removed |
| Can my child live normally with one kidney? | Yes, in almost all cases |
| Can CMN come back after surgery? | Occasionally, mostly within the first year and usually in cellular tumours |
| Can my baby be breastfed? | Yes; breastfeeding can usually continue before and after surgery |
| How is it different from Wilms tumour? | CMN occurs earlier in life and usually needs surgery alone |
12. Questions to ask your care team
- What subtype is the tumour?
- Was the tumour completely removed?
- Does the tumour carry the ETV6-NTRK3 fusion?
- What is the risk of recurrence for my baby?
- How often will scans be needed?
- Does my baby need blood pressure medicines before or after surgery?
- Where should my baby be delivered if the tumour was found before birth?
- Who should I call if my baby becomes unwell?
Resources
- Davis, J.L. et al. (2022) ‘Mesenchymal neoplasms with NTRK and other kinase gene alterations’, Histopathology, 80(1), pp. 4-18.
- Gooskens, S.L. et al. (2017) ‘Congenital mesoblastic nephroma 50 years after its recognition: a narrative review’, Pediatric Blood & Cancer, 64(7), e26437.
- Pachl, M. et al. (2020) ‘Congenital mesoblastic nephroma: a single-centre series’, Annals of the Royal College of Surgeons of England, 102(1), pp. 67-70.
- Vokuhl, C. et al. (2018) ‘ETV6-NTRK3 in congenital mesoblastic nephroma: a report of the SIOP/GPOH nephroblastoma study’, Pediatric Blood & Cancer, 65(4), e26925.
- National Cancer Institute (2026) Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.